Sarah-Jo Sinnott

Sanofi

Poster(s):

• ((A-249)) (A-249) Establishing a repository for background incidence rates of adverse events for use in safety signal assessment
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• ((A-327)) (A-327) The risk of mortality in patients with Multiple Sclerosis treated with alemtuzumab compared to other disease modifying therapies: A cohort study with data from five countries
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET

• ((B-106)) (B-106) Adherence to risk minimization measures for alemtuzumab use in Multiple Sclerosis: a drug utilisation study in four European countries
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• ((B-200)) (B-200) Assessing the Potential Differential Impact of the COVID-19 Pandemic on Cardiovascular Incidence Rates in United States Claims Data
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• ((B-208)) (B-208) Leveraging multiple-country data sources for a comparative drug safety study: complexities and rewards in pharmacoepidemiology
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET